Market Pulse Archives

June 30, 2022, 8:42 a.m. EDT

Blueprint inks deal with Sixth Street, Royalty Pharma worth up to $1.2 billion

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Blueprint Medicines Corp. (BPMC)
  • X
    Royalty Pharma PLC (RPRX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Blueprint Medicines Corp. /zigman2/quotes/209215354/composite BPMC -2.00% gained 3.3% in premarket trading on Thursday after the company announced a deal with investment firm Sixth Street and Royalty Pharma /zigman2/quotes/205762709/composite RPRX +0.96% , which acquires pharmaceutical royalties, worth up to $1.2 billion. Sixth Street will pay $250 million upfront for future royalties for two products, up to $400 million in a senior secured credit facility, and $260 million in a potential credit facility to support any buy-side business opportunities. Royalty Pharma will pay $175 million for royalties for some sales of cancer-drug Gavreto, with up to $165 million in potential milestones. Blueprint's stock is down 51.2% this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +0.19% has declined 19.9%.

/zigman2/quotes/209215354/composite
US : U.S.: Nasdaq
$ 68.55
-1.40 -2.00%
Volume: 607,430
Aug. 16, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.18 billion
Rev. per Employee
$465,632
loading...
/zigman2/quotes/205762709/composite
US : U.S.: Nasdaq
$ 44.35
+0.42 +0.96%
Volume: 2.00M
Aug. 16, 2022 4:00p
P/E Ratio
41.31
Dividend Yield
1.71%
Market Cap
$26.60 billion
Rev. per Employee
$34.24M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,305.20
+8.06 +0.19%
Volume: 2.22B
Aug. 16, 2022 5:48p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.